Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (444)	11/24/1997 10:23:00 AM
From: Rainforest	Read Replies (1) \| Respond to of 1972

Hi, Tony. Thanks for the quick post. It seems that the report is generally in line with reports of previous trials, which Alan Embring has indicated to me is what they are looking for. They want consistent results among the various trials. However, the report of the presentations of Drs Hersh & Gleich from the Arizona and Cincinnati centers is ambiguous. Do they mean that the updated data confirm the efficacy of Allovectin or only that they updated studies which had previously confirmed Allovectin's efficacy? I think we need to clarify that point with Alan later in the day.